File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0031713430
- PMID: 9796835
- WOS: WOS:000076071700003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Conference Paper: Endothelial dysfunction and inhibition of converting enzyme
Title | Endothelial dysfunction and inhibition of converting enzyme |
---|---|
Authors | |
Keywords | Converting enzyme Endothelial cells Endothelium-derived hyperpolarizing factor Kinins Nitric oxide |
Issue Date | 1998 |
Publisher | Oxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/ |
Citation | European Heart Journal, 1998, v. 19 SUPPL. J, p. J7-J15 How to Cite? |
Abstract | Endothelial cells control the tone of the underlying vascular smooth muscle by secreting vasodilator substances (prostacyclin, nitric oxide and endothelium-derived hyperpolarizing factor). These vasodilator substances also contribute to the antithrombogenicity of the normal endothelium, and inhibit cellular growth. In coronary vascular disease, the ability of the endothelium to secrete vasodilator substances is reduced, while the propensity to release endothelium-derived contracting factors is increased. In particular, the reduced release of nitric oxide in response to aggregating platelets, thrombin and circulating catecholamines favours the occurrence of thrombosis and vasospasm, and plays a key role in the initiation of the atherosclerotic process. From the therapeutic point of view, the best available way to enhance the release of endothelium-derived nitric oxide and hyperpolarizing factor is to inhibit converting enzyme. This will protect endogenous bradykinin from breakdown and prolong its action on endothelial receptors. |
Persistent Identifier | http://hdl.handle.net/10722/173532 |
ISSN | 2023 Impact Factor: 37.6 2023 SCImago Journal Rankings: 4.091 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vanhoutte, PM | en_US |
dc.date.accessioned | 2012-10-30T06:32:32Z | - |
dc.date.available | 2012-10-30T06:32:32Z | - |
dc.date.issued | 1998 | en_US |
dc.identifier.citation | European Heart Journal, 1998, v. 19 SUPPL. J, p. J7-J15 | en_US |
dc.identifier.issn | 0195-668X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173532 | - |
dc.description.abstract | Endothelial cells control the tone of the underlying vascular smooth muscle by secreting vasodilator substances (prostacyclin, nitric oxide and endothelium-derived hyperpolarizing factor). These vasodilator substances also contribute to the antithrombogenicity of the normal endothelium, and inhibit cellular growth. In coronary vascular disease, the ability of the endothelium to secrete vasodilator substances is reduced, while the propensity to release endothelium-derived contracting factors is increased. In particular, the reduced release of nitric oxide in response to aggregating platelets, thrombin and circulating catecholamines favours the occurrence of thrombosis and vasospasm, and plays a key role in the initiation of the atherosclerotic process. From the therapeutic point of view, the best available way to enhance the release of endothelium-derived nitric oxide and hyperpolarizing factor is to inhibit converting enzyme. This will protect endogenous bradykinin from breakdown and prolong its action on endothelial receptors. | en_US |
dc.language | eng | en_US |
dc.publisher | Oxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/ | en_US |
dc.relation.ispartof | European Heart Journal | en_US |
dc.subject | Converting enzyme | - |
dc.subject | Endothelial cells | - |
dc.subject | Endothelium-derived hyperpolarizing factor | - |
dc.subject | Kinins | - |
dc.subject | Nitric oxide | - |
dc.subject.mesh | Angiotensin-Converting Enzyme Inhibitors - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Bradykinin - Drug Effects - Metabolism | en_US |
dc.subject.mesh | Coronary Disease - Drug Therapy - Etiology - Metabolism | en_US |
dc.subject.mesh | Endothelium, Vascular - Drug Effects - Secretion | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Nitric Oxide - Metabolism | en_US |
dc.subject.mesh | Peptidyl-Dipeptidase A - Metabolism | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.title | Endothelial dysfunction and inhibition of converting enzyme | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 9796835 | - |
dc.identifier.scopus | eid_2-s2.0-0031713430 | en_US |
dc.identifier.volume | 19 | en_US |
dc.identifier.issue | SUPPL. J | en_US |
dc.identifier.spage | J7 | en_US |
dc.identifier.epage | J15 | en_US |
dc.identifier.isi | WOS:000076071700003 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.issnl | 0195-668X | - |